chemieunternehmen.com

Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestones-in-multi-target-deal-with-ucb-5175

Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-integrated-alliance-with-astrazeneca-in-kidney-disease-5173

Evotec AG today announced the publication of its fourth DDup edition. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-4—epigenetics-5170

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-hold-rd-day-2013-5169

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-exploration-of-enteroendocrine-signals-affecting-key-metabolic-pathways-5165

Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-special-edition—drug-discovery-services-5158

Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-stem-cell-institute-form-curemn-collaboration-to-advance-als-research-5157

Evotec AG today announced a 9.9% increase of its share capital.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-raises-eur-30-m-from-biotechnology-value-fund-5155

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec’s assay development and screening capabilities to support the Jain Foundation’s goals of understanding and curing dysferlinopathy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-announce-extension-of-research-collaboration-in-skeletal-muscular-dystrophy-diseases-5153